Elon Musk did not invent the GLP-1 era. He did something almost as powerful: he made it feel publicly discussable.
In October 2022, when a follower asked how he was looking “fit, ripped, and healthy,” Musk answered with the kind of compressed reply only X can make famous: fasting, then Wegovy. Business Insider later summarized the moment and noted that Musk said he had lost about 20 pounds. A month later, other outlets reported him saying he was “Down 30 lbs!” and crediting “Fasting + Ozempic/Wegovy + no tasty food near me.”
That sentence is basically the entire modern weight-loss conversation in one strange little haiku: appetite biology, food environment, social pressure, and a billionaire being weirdly honest online.
Then came Christmas 2024. Musk posted himself in a Santa suit, called it “Ozempic Santa,” and then clarified the joke. According to Axios, he added: “Technically, Mounjaro, but that doesn’t have the same ring to it.”
That is why Musk’s peptide story is worth understanding. It is not a clean clinical case study. It is a messy, funny, culturally important example of how GLP-1 and GIP-based medicines moved from endocrinology offices into everyday conversation.
What Musk actually said
The timeline matters because people often flatten every celebrity GLP-1 story into one word: Ozempic.
Musk’s first widely cited disclosure was not “Ozempic.” In 2022 he pointed to Wegovy, the higher-dose semaglutide product approved for chronic weight management. Later that year, he also used the phrase “Ozempic/Wegovy,” which makes sense culturally because both brands contain semaglutide, but it is not the same as saying the products are interchangeable.
By 2024, the public reference changed again. The Santa post used “Ozempic” because the word had become shorthand for the entire category. But Musk’s clarification pointed to Mounjaro, whose active ingredient is tirzepatide. Tirzepatide acts on two incretin hormone pathways: GLP-1 and GIP.
That distinction is not trivia. It is the difference between:
- Wegovy: semaglutide, a GLP-1 receptor agonist approved for chronic weight management.
- Ozempic: semaglutide, approved for type 2 diabetes, with weight loss often discussed as a secondary effect.
- Mounjaro: tirzepatide, approved for type 2 diabetes.
- Zepbound: tirzepatide, approved for chronic weight management.
So the clean version of the story is this: Musk publicly linked his weight-loss transformation first to fasting plus Wegovy, then later joked about Ozempic while clarifying he meant Mounjaro. The public heard “Ozempic.” The pharmacology says: semaglutide first, tirzepatide later.
Why the drugs helped
GLP-1 medications work partly because they make the modern food environment less loud.
Wegovy is semaglutide, a GLP-1 receptor agonist. The FDA-approved Wegovy label describes it as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. In plain English: it is not supposed to be a magic shot floating outside behavior. It is a medical tool layered onto diet and movement.
The mechanism is what makes it feel different from old-school dieting. GLP-1 signaling can slow stomach emptying, increase fullness, and reduce appetite drive. People often describe the experience as food becoming quieter. The cookies are still there; the mental emergency around the cookies may be lower.
That is where Musk’s “no tasty food near me” line becomes more interesting than it first sounds. It is not just a joke. It is environmental design. If the medication lowers appetite and the environment removes easy triggers, the behavior gets easier.
Fasting adds another layer. Musk had also talked about intermittent fasting and using the Zero fasting app before the GLP-1 comments became famous. Time-restricted eating can reduce total intake for some people, but it is not magic either. It works when it creates a sustainable calorie deficit without turning life into a nightly cage match with the refrigerator.
The educational takeaway: Musk did not describe one lever. He described a stack.
Medication lowered appetite. Fasting reduced eating windows. Food-environment control reduced temptation. Public accountability probably did not hurt. That is the boring, useful version of the “success story.”
Why Mounjaro changed the conversation
Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist. The FDA label for Mounjaro describes it as a medication used with diet and exercise to improve glycemic control in adults with type 2 diabetes.
For weight management, the same active ingredient is sold as Zepbound. The FDA approved Zepbound in November 2023, noting that tirzepatide activates GLP-1 and GIP hormone receptors and is used with reduced calories and increased physical activity for eligible adults with obesity or overweight.
In the larger Zepbound trial cited by the FDA, adults without diabetes receiving the highest approved dose lost an average of 18% of body weight after 72 weeks, compared with placebo. That does not mean every person gets that result. It does explain why the category exploded.
Musk’s 2024 “technically, Mounjaro” comment landed after the public had already learned the word Ozempic. By then, “Ozempic” had become a cultural noun, like Kleenex or Xerox. But tirzepatide is a different molecule, and for many patients it can produce different appetite and side-effect experiences.
Musk reportedly said he preferred Mounjaro because of fewer side effects. That is an individual report, not a medical rule. GLP-1 and GIP-based medicines can cause nausea, diarrhea, vomiting, constipation, reflux, burping, fatigue, gallbladder issues, and more serious risks in some patients. The “success” part only counts when the risk/benefit math works for the individual patient under medical supervision.
The Musk effect was measurable
Here is the wildest part: researchers actually studied whether Musk’s comments changed medication use.
A 2024 PubMed-indexed time-series analysis in Recenti Progressi in Medicina looked at semaglutide use in Italy’s Lazio Region after Musk publicly credited Wegovy in October 2022. The researchers found no overall increase in new users across the whole GLP-1 class, but they did see a shift toward semaglutide: monthly average new semaglutide users rose from 872 before Musk’s comments to 1,380 after, while other GLP-1 drugs fell from 711 to 208.
The authors were careful. They did not claim Musk alone caused everything. They concluded his statements seemed to have had an impact and that more analysis was needed.
That is still remarkable. A two-word celebrity reply became visible enough that researchers could ask whether it moved prescribing patterns in a regional health system.
Most celebrity wellness stories vanish after a news cycle. Musk’s became part of the evidence trail.
What we can learn from it
The lesson is not “be Elon.” Please do not build a health plan around billionaire replies.
The lesson is also not “take whatever medication a famous person jokes about.” Musk has money, access, physicians, and a tolerance for public chaos that should not be generalized to normal life.
The useful lessons are more grounded:
- Appetite is biology, not just discipline. GLP-1 and GIP drugs became popular because they affect satiety signals that many people cannot brute-force forever.
- Lifestyle still matters. Musk did not say the drug worked in isolation. He named fasting and food environment too.
- Brand names get messy fast. Ozempic, Wegovy, Mounjaro, and Zepbound are not the same thing, even when the internet uses them as one giant synonym.
- Public figures move behavior. Musk’s comments did not just entertain people. They appear to have nudged interest in semaglutide.
- Medical channels matter. These are prescription drugs, not casual wellness hacks.
If you want to explore peptide science more broadly, Best Days carries research-grade peptides for laboratory research in areas like recovery, performance, and longevity. Those products are not for human consumption. That is a different category from prescription GLP-1 medications. Best Days does not sell Wegovy, Ozempic, Mounjaro, Zepbound, semaglutide, or tirzepatide.
That distinction is important because the internet has blurred the terms “peptide,” “GLP-1,” “research chemical,” and “prescription drug” into one muddy bucket. Musk’s story is about FDA-regulated medicines used through medical channels, not gray-market vials.
The real success story
The entertaining version of the story is “Ozempic Santa.”
The educational version is better: Musk was one of the first ultra-famous people to make GLP-1-assisted weight loss feel speakable in public. He framed his result as a combination of appetite support, fasting, and less access to tempting food. Then, as the category evolved, he moved from Wegovy references to Mounjaro references and made the whole topic even more mainstream.
That is the real success story. Not that a rich person got thinner. That happens every week.
The more important thing is that Musk helped drag appetite biology out of the shame closet. For better and worse, he made millions of people ask a more serious question: what if obesity treatment is not only about willpower, but about hormones, food environment, access, and long-term medical support?
That question is bigger than Musk. And unlike a Christmas costume post, it might actually age well.
Readers who want a deeper research-oriented look at non-GLP-1 peptides can browse the Best Days shop. For FDA-approved GLP-1 or GIP/GLP-1 medications, talk with a licensed clinician who can evaluate your medical history, risk factors, current medications, and goals.
Editorial note: This article is for general information only and is not medical advice. Prescription medicines such as Wegovy, Ozempic, Mounjaro, and Zepbound should be discussed with a qualified healthcare professional. Biohack Library has a commercial relationship with Best Days and may earn revenue from purchases made through Best Days links.